Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
about
Tumor angiogenesis: pericytes and maturation are not to be ignoredColorectal cancer tumour markers and biomarkers: Recent therapeutic advancesProfile of bevacizumab and its potential in the treatment of cervical cancerRecent applications of chemosensitivity tests for colorectal cancer treatmentLessons learned from the bevacizumab experienceEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft modelsGene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsMMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careLysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesisNotch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signallingClinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertensionMore sound cancer therapy biomarker development with active noise control.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialCisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing ChemotherapyPrognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.Biomarkers for antitumor activity of bevacizumab in gastric cancer models.Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensTissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy.An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]Biomarkers for anti-angiogenic therapy in cancer.Role of activated Rac1/Cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer.Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of PazopanibA randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
P2860
Q21296683-64E28012-8336-4BDE-91EC-9636E7394798Q26768427-3CA4439F-CA6E-42FA-A40F-09F4BB4AD298Q26774168-A3119172-ABEA-440C-9F3D-0ABFDD5EC797Q26851075-9562591C-E972-488D-963C-1D12219B598AQ26852509-A93BD891-34A2-4750-86E0-A2F8B19A0301Q26995204-E14D0932-545D-4317-9FA7-5226D09FA372Q27002538-B4160D80-4424-461E-9BB7-6A858CBE3582Q27302122-958DD3DF-ABA1-415B-AA4C-018DF2BDDE99Q27852191-BD751F58-BB18-4558-A6B2-EA112522931FQ27852713-411A3293-6527-49D6-96D4-535DEBA0C744Q27853168-504DB100-3E7A-41D1-931E-003E6766FBC1Q27853354-D59316E5-5396-461D-882A-E86DA26AE418Q27853384-A301F55E-D8FC-4E0F-AAB1-CFEBDFCB39CDQ28066460-E9E50FD3-021C-4399-8190-ED433607959DQ28280138-F17C8E34-6C47-4E05-8D16-2A7733A10F07Q28587298-7EF542E1-A106-4C85-96AE-06147E38C91CQ28728389-B68E110B-7EB3-4142-AD95-D4495684A703Q30442454-92642286-5DBD-4CBD-8585-C7736A833362Q30537414-B15E43E5-B7D5-4C1B-9A7C-536C1AFDA19EQ33397464-561B1EDE-F0D9-4319-B682-A51EFBCC807EQ33414769-C8679C08-7E76-4799-B147-D1EAD45CC498Q33418595-37E8DB9B-6D40-4855-9679-A224C23760FFQ33680243-D84FB355-E852-4886-86F0-CCF964E9A06CQ33770680-4A08E5B0-4525-45FA-A232-6D1EA4C2B545Q33820865-8D6E7D07-8DB6-44CB-A311-691E409EE648Q33877467-58C234E0-5682-4645-8F77-2B74FCB90DA9Q34138326-553FAB76-71A8-4AAF-88B9-8EB5583F693FQ34153021-41FD2309-0675-4A5A-BD69-973E1D819158Q34309960-E9322BFA-5B5C-4C9B-8E74-BA21427C1424Q34343614-B80B24E8-7707-47BD-AF82-E6656646038EQ34523039-2B41B8C8-5D58-4BF8-B059-78ECD0BEDE4CQ34623196-E7256033-0A7E-4251-9EC5-1E269943D09FQ34695003-BE11A74B-4084-44B1-9903-67A792791B1BQ34764393-DCB08BE8-EC86-49F7-8C39-B0234F71F01BQ34897393-82E48BA3-DD44-4512-94B2-7F842C88F788Q34953306-BDF12803-374D-42AD-983B-FDA2DA209164Q34999120-F580EE34-9D1D-40BA-B6CC-34D14C105120Q35068932-1418DF15-A0ED-449F-B6B0-393CDB0ADE07Q35129364-250B45D7-4C6E-46A2-836B-B6078FCE9875Q35217801-51EB218B-6FD9-4B1F-B73D-2DF9AB4B95DE
P2860
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@en
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@nl
type
label
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@en
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@nl
prefLabel
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@en
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@nl
P1433
P1476
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
@en
P2093
Adrian M Jubb
P304
P356
10.1016/S1470-2045(10)70232-1
P577
2010-12-01T00:00:00Z